AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

Please cancel claims 4, 8, and 17 without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

Claim 1 (Currently amended): A method for providing dopamine or a dopamine precursor to a dopamine deficient prefrontal cortex of a subject with schizophrenia, comprising administering a cell/support complex to the prefrontal cortex of the subject's brain, wherein said cell/support complex comprises cells adhered to a support matrix, wherein said cells produce dopamine or a dopamine precursor,

wherein the cells are selected from the group consisting of retinal pigment epithelial cells, chromaffin cells, cells of neural origin, paraneural cells, and cells derived from the adrenal medulla, and

wherein said support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

Claim 2 (Original): The method of claim 1, wherein said cell/support complex is administered to the subject by injection.

Claim 3 (Original): The method of claim 1, wherein said cell/support complex is administered to the subject by implantation.

Claim 4 (Canceled)

Claim 5 (Currently amended): The method of claim [[4]] 1, wherein said support matrix is gelatin or modified gelatin.

Claim 6 (Previously presented): The method of claim 5 wherein said support matrix is crosslinked gelatin.

Claim 7 (Canceled)

Claim 8 (Canceled)

Claim 9 (Currently amended): The method of claim [[8]] 1 wherein the cells produce a dopamine precursor.

Claim 10 (Currently amended): The method of claim [[8]] 1 wherein the cells produce dopamine.

Claim 11 (Currently amended): The method according to claim [[8]] 1 wherein the cells are retinal pigment epithelium (RPE) cells.

Claim 12 (Original): The method of claim 1 wherein the subject is a human.

Claims 13-18 (Canceled)

Claim 19 (Withdrawn): A method for treating extrapyramidal side effects (EPS) produced by antipsychotic drugs, comprising administering an effective amount of a cell/support complex comprising therapeutic cells to a site in said subject's brain, wherein said cell/support complex comprises therapeutic cells which produce dopamine or a dopamine precursor adherent to a first support matrix, thereby alleviating said symptoms.

Claim 20 (Withdrawn): The method of claim 19 wherein said EPS is tardive dyskinesia.

Claim 21 (Withdrawn): The method of claim 20 wherein said cell/support matrix is administered to the striatal area of said subject's brain.

Claim 22 (Withdrawn): The method of claim 21 wherein said cell/support matrix is administered by injection.

Claim 23 (Withdrawn): The method of claim 21 wherein said cell/support matrix is administered by implantation.

Claim 24 (Withdrawn): The method of claim 21 wherein said first support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

Claim 25 (Withdrawn): The method of claim 24, wherein said first support matrix is gelatin or modified gelatin.

Claim 26 (Withdrawn): The method of claim 25 wherein said first support matrix is crosslinked gelatin.

Claim 27 (Withdrawn): The method of claim 21, wherein the therapeutic cells are selected from the group consisting of retinal pigmented epithelial cells, human foreskin fibroblasts, chromaffin cells, cells of neural origin, paraneural cells, cells engineered by somatic cell hybridization, cells derived from the adrenal medulla, and cells that have been genetically engineered to express a biologically active compound.

Claim 28 (Withdrawn): The method of claim 27 wherein the therapeutic cells produce a dopamine precursor.

Claim 29 (Withdrawn): The method of claim 27 wherein the cells produce dopamine.

Claim 30 (Withdrawn): The method according to claim 29 wherein the therapeutic cells are retinal pigmented epithelium (RPE) cells.

Claim 31 (Withdrawn): The method of claim 21 wherein the subject is a human.

Claim 32 (Withdrawn): The method of claim 21 wherein said cell/support complex further comprises protective cells.

Claim 33 (Withdrawn): The method of claim 32 wherein said cell/support complex further comprises support cells.

Claim 34 (Withdrawn): The method of claim 21 wherein said cell/support complex further comprises protective cells adherent to a second support matrix.

Claim 35 (Withdrawn): The method of claim 34 wherein said cell/support complex further comprises support cells adherent to a third support matrix.

Claim 36 (Withdrawn): A method for improving cognitive deficits associated with schizophrenia, comprising administering an effective amount of a cell/support complex comprising therapeutic cells to a site in said subject's brain, wherein said cell/support complex comprises therapeutic cells which produce dopamine or a dopamine precursor adherent to a first support matrix, thereby alleviating said cognitive deficits.

Claims 37-43 (Cancelled)

Claim 44 (New): The method of claim 1 wherein the cell/support complex is administered to the dorsolateral prefrontal cortex of the subject's brain.